Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NB-UVB Clear all
Suspended Early Phase 1 Interventional

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)

NCT06235281
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
Mogamulizumab-Kpkc, Phototherapy
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 18, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional

UVB Phototherapy Treatment of Oral Chronic GVHD

NCT00374257
View directory record Official record
Conditions
Oral Chronic Graft-versus-host Disease
Interventions
Narrow-Band UVB Phototherapy
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
4 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 18, 2026, 2:23 PM EDT
Terminated Not applicable Interventional Results available

Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo

NCT02506101
View directory record Official record
Conditions
Vitiligo, Pigmentation, Dyschromia
Interventions
narrow-band ultraviolet B phototherapy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients

NCT04818970
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Autoimmune Diseases, Coagulation Disorder, Blood
Interventions
Narrow Band ultraviolet B-Band Light, non Narrow Band ultraviolet B-Band Light
Device
Lead sponsor
Cytokind, Inc.
Industry
Eligibility
50 Years to 110 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis Trial (The VIP Trial)

NCT01553058
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab (Humira), Placebo Injection, NB-UVB phototherapy
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis

NCT00800982
View directory record Official record
Conditions
Psoriasis
Interventions
Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

NCT05971381
View directory record Official record
Conditions
Vitiligo
Interventions
RECELL® Autologous Cell Harvesting Device
Device
Lead sponsor
Avita Medical
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Scottsdale, Arizona • Irvine, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Narrowband UVB Treatment in Patients With Vitiligo

NCT00398723
View directory record Official record
Conditions
Vitiligo
Interventions
Narrowband UVB
Device
Lead sponsor
Mary Sullivan-Whalen
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)

NCT01430195
View directory record Official record
Conditions
Vitiligo
Interventions
Afamelanotide, Narrow-Band UVB Light Treatment
Drug · Procedure
Lead sponsor
Clinuvel Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Not applicable Interventional Results available

Psoriasis Microbiome and Phototherapy

NCT02552316
View directory record Official record
Conditions
Psoriasis
Interventions
NB-UVB Phototherapy
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Not applicable Interventional Results available

NB-UVB Phototherapy With and Without Topical LCD Treatment: a Bilateral Pilot Study

NCT00708851
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
LCD Solution with NB-UVB Phototherapy, NB-UVB Light Device (311-315 nm)
Other · Device
Lead sponsor
NeoStrata Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Not applicable Interventional Results available

Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis

NCT02107482
View directory record Official record
Conditions
Psoriasis
Interventions
Levia Narrow Band UVB, Levia sham/visible-light source
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 18, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

NCT04811131
View directory record Official record
Conditions
Vitiligo
Interventions
ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment, NB-UVB phototherapy sham treatment
Drug · Device
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Rolling Meadows, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Phase 4 Interventional

NB-UVB and PUVA Vitiligo Study

NCT01732965
View directory record Official record
Conditions
Vitiligo
Interventions
Phototherapy, Phototherapy and Photochemotherapy
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy

NCT03270241
View directory record Official record
Conditions
Vitiligo, Dermatology/Skin - Other
Interventions
Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

NCT03123016
View directory record Official record
Conditions
Vitiligo
Interventions
Apremilast, NB-UVB phototherapy
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Phase 1Phase 2 Interventional

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

NCT00050661
View directory record Official record
Conditions
Psoriasis
Interventions
Daclizumab, NB-UVB
Drug · Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Narrowband UVB Phototherapy on Systemic Inflammation in Patients With Atopic Dermatitis

NCT03083730
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Narrow band UVB treatment (NB-UVB)
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 18, 2026, 2:23 PM EDT
Terminated Not applicable Interventional Results available

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

NCT00724061
View directory record Official record
Conditions
Lymphoma
Interventions
Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 18, 2026, 2:23 PM EDT
Terminated Not applicable Interventional

Comparing the Efficacy of Visible Light-Ultraviolet A1 Light Versus Narrowband-Ultraviolet B on Generalized Vitiligo

NCT05238077
View directory record Official record
Conditions
Generalized Vitiligo
Interventions
Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 18, 2026, 2:23 PM EDT
Terminated Phase 1 Interventional

Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris

NCT03662685
View directory record Official record
Conditions
Psoriasis Vulgaris, Psoriasis
Interventions
Goeckerman Therapy, Crude Coal Tar Only, Phototherapy Only
Other · Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 18, 2026, 2:23 PM EDT
Terminated Not applicable Interventional

Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris

NCT00844363
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
NB-UVB
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 18, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

NCT05247489
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib 1.5% cream, NB-UVB phototherapy
Drug · Device
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Fountain Valley, California • Sacramento, California • Sunnyvale, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 18, 2026, 2:23 PM EDT
Active, not recruiting Phase 3 Interventional

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411
View directory record Official record
Conditions
Vitiligo
Interventions
Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 18, 2026, 2:23 PM EDT